Feld R, Rubinstein L V, Weisenberger T H
J Clin Oncol. 1984 Dec;2(12):1352-8. doi: 10.1200/JCO.1984.2.12.1352.
The Lung Cancer Study Group recently completed a double-blind adjuvant immunotherapy study, in which 473 patients with resected stage I non-small-cell lung cancer were randomized to either intrapleural BCG or placebo. The study showed no significant difference in time to first recurrence for the two treatment arms. The present report analyzes the distribution of the anatomic site of first relapse and relates this to TN staging, histology, and other appropriate risk factors. The overall rate of recurrence is significantly higher for increasing TN status and for nonsquamous as compared to squamous-cell type. However, the distribution of site of recurrence does not, in general, change with increasing TN status or with histology. Approximately 65% to 75% of the first recurrences involve distant sites, with the brain being by far the most common, regardless of TN staging or histology. The implications of this for planning future studies is discussed.
肺癌研究组最近完成了一项双盲辅助免疫治疗研究，473例I期非小细胞肺癌切除患者被随机分为胸膜内注射卡介苗或安慰剂组。该研究显示，两个治疗组首次复发时间无显著差异。本报告分析了首次复发的解剖部位分布，并将其与TN分期、组织学及其他相关风险因素联系起来。总体复发率随TN分期增加及非鳞状细胞癌（与鳞状细胞癌相比）而显著升高。然而，复发部位的分布一般不会随TN分期增加或组织学类型而改变。无论TN分期或组织学类型如何，约65%至75%的首次复发累及远处部位，其中脑是迄今为止最常见的部位。本文讨论了这一结果对未来研究规划的影响。
